FDA Determines Regulatory Review Period for Intercept Blood System for Platelets Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Intercept's platelet blood system, a medical device, in accordance with patent extension laws, following a submission to the US Patent and Trademark Office (USPTO).